Remidio

Remidio develops portable, clinically validated, AI-powered retinal imaging devices and telemedicine platforms for screening and diagnosing eye diseases such as diabetic retinopathy, glaucoma, AMD, and cataracts. Their smartphone-based, non-mydriatic fundus cameras (not requiring pupil dilation) enable high-quality retinal imaging by both specialists and non-specialists, even in remote settings. Remidio’s AI algorithms (Medios series) can detect referable diabetic retinopathy, glaucoma, and AMD offline, facilitating use in areas with limited connectivity. The company is expanding its technology for early detection of systemic diseases via retinal biomarkers. Devices are CE marked, FDA 510(k) cleared, and used in over 40 countries, having screened over 16 million patients globally.